SOKA, Japan–(BUSINESS WIRE)–Lightnix Inc. (2-3-9 Takasago, Soka-shi, Saitama Prefecture; CEO: Shosuke Kiba) has decided to participate as a partner company in “Innovation Infusion Japan� (“i2.JP”; Website: https://www.i2jp.net/en/index.html), an initiative sponsored by AstraZeneca K.K. (Kita-ku, Osaka-shi, Osaka Prefecture; President: Takafumi Horii).
i2.JP is a new initiative that promotes open innovations in the healthcare field. Its goal is to contribute to next-generation healthcare through partnerships with companies, academia, and government.
Lightnix seeks to create innovations in healthcare through the development of intradermal vaccine injection devices and other new drug delivery methods.
By leveraging its strengths in this field, the company aims to resolve healthcare issues related to vaccine and drug delivery in partnership with both the public and private sectors, including the healthcare sector and industries worldwide participating in i2.JP.
Contacts
Lightnix Inc.
Akihiro ISUMI, General Manager
+81-48-951-3637
info@lightnix.jp
https://www.lightnix.jp/en/
LONDON--(BUSINESS WIRE)--Palliser Capital (“Palliser”), the eighth largest shareholder of Keisei Electric Railway Co., Ltd. (9009…
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical…
DUBLIN--(BUSINESS WIRE)--The "Singapore Construction Equipment Market - Strategic Assessment & Forecast 2024-2029" report has been…
AUCKLAND, New Zealand--(BUSINESS WIRE)--Serko Limited today announced it has signed a five-year contract with Booking.com…
GanNA founders include Carolyn Bertozzi, Ph.D., Richard D. Cummings, Ph.D., Ryan A. Flynn, M.D., Ph.D.,…
NASA’s PREFIRE mission requires two satellites to be deployed to precise orbits one after the…
